PMID- 25004024
OWN - NLM
STAT- MEDLINE
DCOM- 20150625
LR  - 20171116
IS  - 1473-5733 (Electronic)
IS  - 0957-5235 (Linking)
VI  - 25
IP  - 8
DP  - 2014 Dec
TI  - Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup 
      analysis on the efficacy and safety of certoparin vs. unfractionated heparin.
PG  - 838-44
LID - 10.1097/MBC.0000000000000166 [doi]
AB  - The objective of this subgroup analysis of the pivotal studies NMH-TH-3 and 
      NMH-TH-4 was to investigate the incidence of recurrent events of venous 
      thromboembolism in patients with acute deep vein thrombosis (DVT) with and 
      without pulmonary embolism treated with subcutaneous fixed-dose 
      low-molecular-weight heparin certoparin or intravenous unfractionated heparin 
      (UFH). To assess whether the efficacy of the two treatments is modified by the 
      presence or absence of pulmonary embolism, a P value for subgroup by treatment 
      interaction was calculated using logistic regression. The rate of recurrent 
      venous thromboembolic events, defined as DVT, pulmonary embolism and death due to 
      pulmonary embolism, was observed over 6 months. After 6 months of follow-up, 
      6.58% of patients with pulmonary embolism at baseline treated with certoparin 
      (5/76) compared with 11.5% of patients with pulmonary embolism at baseline 
      treated with UFH (7/61) had a venous thromboembolic event [relative risk (RR) = 
      0.57, confidence interval (CI) = 0.19-1.72]. In the group of patients without 
      pulmonary embolism at baseline, 2.82% of patients treated with certoparin 
      (23/816) and 4.63% of patients treated with UFH (37/800) had a venous 
      thromboembolic event (RR = 0.61, CI = 0.37-1.02). The test for interaction 
      between the groups of patients with and without pulmonary embolism was not 
      significant (P = 0.886). The same was true for the safety results with regard to 
      major bleedings and death. These data suggest that the recommendation for the use 
      of certoparin in the treatment of isolated DVT can safely be extended to 
      treatment of DVT in patients concomitantly suffering from pulmonary embolism.
FAU - Riess, Hanno
AU  - Riess H
AD  - aCharite Campus Virchow Klinikum, Berlin bNovartis Pharma GmbH, Nuremberg 
      cUniversity Hospital Mannheim, Ruprecht-Karls-University, Heidelberg, Germany.
FAU - Becker, Lena K
AU  - Becker LK
FAU - Melzer, Nima
AU  - Melzer N
FAU - Harenberg, Job
AU  - Harenberg J
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
RN  - V72OT3K19I (certoparin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Injections, Intravenous
MH  - Injections, Subcutaneous
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Pulmonary Embolism/blood/complications/*drug therapy/mortality
MH  - Recurrence
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Venous Thrombosis/blood/complications/*drug therapy/mortality
EDAT- 2014/07/09 06:00
MHDA- 2015/06/26 06:00
CRDT- 2014/07/09 06:00
PHST- 2014/07/09 06:00 [entrez]
PHST- 2014/07/09 06:00 [pubmed]
PHST- 2015/06/26 06:00 [medline]
AID - 10.1097/MBC.0000000000000166 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2014 Dec;25(8):838-44. doi: 
      10.1097/MBC.0000000000000166.